Magnetic Fields in the Treatment Of Parkinson's Disease

References

• Aldegunde M., Miquez I., Veira J. Effects of pinealectomy on regional brain serotonin metabolism. International Journal of Neuroscience 1985; 26: 9–13
   PubMed Web of Science ®Google Scholar
• Anninos P. A., Tsagas N., Sandyk R., Adamopoulos A. A. Attenuation of epilepsy with application of external magnetic fields: A case report. International Journal of Neuroscience, (in press)
   Google Scholar
• Anninos P. A., Tsagas N., Sandyk R., Derpapas K. Magnetic stimulation in the treatment of partial seizures. International Journal of Neuroscience 1991; 60: 141–171
   PubMed Web of Science ®Google Scholar
• Anton-Tay F. Melatonin: effects on brain function. Advances in Biochemical Psychopharma-cology 1974; 11: 315–324
   PubMedGoogle Scholar
• Anton-Tay F., Diaz J. L., Fernandez-Guardiola A. On the effects of melatonin upon human brain. Its possible therapeutic implications. Life Sciences 1971; 10: 841–850
   Web of Science ®Google Scholar
• Bradbury A. J., Kelly M. E., Smith J. A. Melatonin action in the mid-brain can regulate dopamine function both behaviourally and biochemically. The pineal gland: endocrine aspects, G. M. Brown, S. D. Wainwright. Pergamon Press, Oxford 1985; 327–332
   Google Scholar
• Chase T. N., Juncos J., Serrati C, Fabbrini G., Bruno G. Fluctuations in response to chronic levodopa therapy: pathogenetic and therapeutic considerations. Advances in Neurology, M. D. Yahr, K. J. Bergmann. Raven Press, New York 1986; vol. 45: 477–480
   Google Scholar
• Cotzias G. C., Tang L. C., Miller S. T., Ginos J. Z. Melatonin and abnormal movement induced by L-dopa in mice. Science 1971; 173: 450–452
   PubMed Web of Science ®Google Scholar
• Cremer-Bartels G., Krause K., Kuechle H. J. Influence of low magnetic field-strength variations on the retina and pineal gland of quails and humans. Graefe's Archives of Clinical and Experimental Ophthalmology 1983; 220: 248–252
   PubMed Web of Science ®Google Scholar
• Cremer-Bartels G., Krause K., Mitoskas G., Brodersen D. Magnetic field of the earth as additional Zeitgeber for endogenous rhythms?. Naturwissenschaften 1984; 71: 567–574
   PubMed Web of Science ®Google Scholar
• De Lorge J. Effects of magnetic fields on behavior in nonhuman primates. Magnetic field effects in biological systems, T. Tenforde. Plenum Press, New York 1979; 32
   Google Scholar
• Duvoisin R. C. New Strategies in dopaminergic therapy of Parkinson's disease: The use of a controlled-release formulation. Neurology 1989; 39: 4–6, (suppl 2)
   PubMedGoogle Scholar
• Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiology. Movement disorders, C. D. Marsden, S. Fahn. Butterworths Scientific, London 1982; 123–145
   Google Scholar
• Granerus A. K., Carlsson A., Svanborg A. The aging neuron: influence on symptomatology and therapeutic response in Parkinson's syndrome. Advances in Neurology 1979; 24: 327–334
   Google Scholar
• Haberditzl W. Enzyme activity in high magnetic fields. Nature 1967; 213: 72–73
   Web of Science ®Google Scholar
• Hardie R. J. Levodopa-related motor fluctuations. Parkinson disease, G. Stern. Chapman and Hall Medical, London 1990; 559–596
   Google Scholar
• Holmes S. W., Sugden D. Effects of melatonin on sleep and neurochemistry in the rat. British Journal of Pharmacology 1982; 76: 95–101
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O., Kish S. J. Biochemical pathophysiology of Parkinson's disease. Advances in neurology, M. D. Yahr, K. J. Bergmann. Raven Press, New York 1990; vol. 45: 19–34
   Google Scholar
• Jankovic B. D., Marie D., Ranin J., Veljic J. Magnetic fields, brain and immunity: effect on humoral and cell-mediated immune responses. International Journal of Neuroscience 1991; 59: 25–43
   PubMed Web of Science ®Google Scholar
• Klawans H. L. The pharmacology of extrapyramidal movement disorders. S. Karger, Basel 1973
   Google Scholar
• Klawans H. L., Weiner W. J. Textbook of clinical neuropharmacology. Raven Press, New York 1981
   Google Scholar
• Klawans H. L., Hitri A., Barr A. Levodopa-induced dyskinesias. Parkinson's disease, G. Stern. Chapman and Hall Medical, London 1990; 537–557
   Google Scholar
• Koller W. C., Hubble J. P. Levodopa therapy in Parkinson's disease. Neurology 1990; 40: 40–47, (supp 3)
   Google Scholar
• Kopp N., Claustrat B., Tappaz M. Evidence for the presence of melatonin in the human brain. Neuroscience Letters 1980; 19: 237–242
   PubMed Web of Science ®Google Scholar
• Korsgaard S., Gerlach J., Christensson E. Behavioral aspects of serotonin-dopamine interaction in the monkey. European Journal of Pharmacology 1985; 118: 245–252
   PubMed Web of Science ®Google Scholar
• Laudon M., Nir I., Zisapel N. Melatonin receptors in discrete brain areas of the male rat. Impact of aging on density and on circadian rhythmicity. Neuroendocrinology 1988; 48: 577–583
   PubMed Web of Science ®Google Scholar
• Le Witt P. A., Chase T. N. “On-Off” effects: the new challenge in parkinsonism. Trends in Neuroscience 1983; 6: 1–4
   Google Scholar
• Lissoni P., Esposti D., Esposti G., Mauri R., Resentini M., Morabito F., Fumagali P., Santa-gostino A., Delitala G., Fraschini F. A clinical study on the relationship between the pineal gland and the opioid system. Journal of Neural Transmission 1986; 65: 63–73
   PubMed Web of Science ®Google Scholar
• Mahlum D. D., Sikov M. R., Decker J. R. Dominant lethal studies in mice exposed to direct current magnetic fields. Biological effects of extremely low frequency electromagnetic fields. Conf. 781016, R. D. Phillips, M. F. Gillis. U.S. Department of Energy, 1979
   Google Scholar
• Malinin G. I., Gregory W. D., Morelli L. Evidence of morphological and physiological transformation of mammalian cells by strong magnetic fields. Science 1976; 194: 844–846
   PubMed Web of Science ®Google Scholar
• Marsden C. D. On-Off phenomenon in Parkinson's disease. Parkinson's disease, current progress, problems and management, U. K. Rinne, M. Klinger, G. Stamm. Elsevier, North Holland 1980; 241–254
   Google Scholar
• Muenter M. D., Sharpless N. S., Tyce G. M., Darley F. L. Patterns of dystonia (“I-D-I” and “D-I-D”) in response to L-dopa therapy for Parkinson's disease. Mayo Clinic Proceedings 1977; 52: 163–173
   PubMed Web of Science ®Google Scholar
• Nauta H. J. W. The relationship of the basal ganglia to the limbic system. Handbook of clinical neurology, extrapyramidal disorders, P. J. Vinken, G. W. Bruyn, H. L. Klawans. Elsevier Science Publishers, North Holland 1986; vol. 5: 19–31
   Google Scholar
• Neurath P. W. High gradient magnetic field inhibits embryonic development of frogs. Nature 1968; 219: 1358–1359
   PubMed Web of Science ®Google Scholar
• Niles L. P., Brown G. M., Mishra R. K. Effects of blinding and pinealectomy on regional brain monoamine concentrations. Journal of Neuroscience Research 1983; 10: 53–60
   PubMed Web of Science ®Google Scholar
• Nutt J. C. Levodopa-induced dyskinesia. Neurology 1990; 40: 340–345
   PubMed Web of Science ®Google Scholar
• Obeso J. A., Grandas F., Vaemonde J. Motor complications associated with chronic levo-dopa therapy in Parkinson's disease. Neurology 1989; 11: 11–18, (suppl 2)
   Google Scholar
• Olcese J., Reuss S. Magnetic field effects on pineal gland melatonin synthesis: comparative studies on albino and pigmented rodents. Brain Research 1986; 369: 365–368
   PubMed Web of Science ®Google Scholar
• Olcese J., Reuss S., Semm P. Geomagnetic field detection in rodents. Life Sciences 1988; 42: 605–613
   PubMed Web of Science ®Google Scholar
• Ossenkopp K. P., Cain D. P. Inhibitory effects of acute exposure to low-intensity 60-Hz magnetic fields on electrically kindled seizures in rats. Brain Research 1988; 442: 255–260
   PubMed Web of Science ®Google Scholar
• Papavasiliou P. S., Cotzias G. C., Duby S. E. Melatonin and parkinsonism. Journal of the American Medical Association 1972; 221: 88–89
   PubMed Web of Science ®Google Scholar
• Quinn N. P. Levodopa. Handbook of parkinson's disease, W. C. Roller. Marcel Dekker, New York 1987; 317–337
   Google Scholar
• Rinne U. K., Lonnberg P., Koskinen V. Dopamine receptor changes in Parkinson's disease. Journal of Neural Transmission 1981; 51: 97–106
   PubMed Web of Science ®Google Scholar
• Rosenstein R. E., Cardinali D. P. Melatonin increases in vivo GABA accumulation in rat hypothalamus, cerebellum, cerebral cortex and pineal gland. Brain Research 1986; 398: 403–406
   PubMed Web of Science ®Google Scholar
• Rudolph K., Krauchi K., Wirtz-Justice A., Freer H. Weak 5-Hz electromagnetic fields activate rat open field behavior. Physiology & Behavior 1985; 35: 505–508
   PubMed Web of Science ®Google Scholar
• Sandyk R. Pineal melatonin functions: possible relevance to Parkinson's disease. International Journal of Neuroscience 1990; 50: 37–53
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. Serotonin in movement disorders. International Journal of Neuroscience 1988; 42: 185–205
   PubMed Web of Science ®Google Scholar
• Sandyk R., Anninos P. A., Tsagas N. Magnetic fields and the habenular complex. International Journal of Neuroscience 1991; 59: 263–266
   PubMed Web of Science ®Google Scholar
• Semm P. Neurobiological investigations on the magnetic sensitivity of the pineal gland in rodents and pigeons. Comparative Biochemistry and Physiology 1983; 76A: 683–689
   Web of Science ®Google Scholar
• Semm P., Schneider T., Vollrath L. Effects of an earth-strength magnetic field on electrical activity of pineal cells. Nature 1980; 288: 607–608
   PubMed Web of Science ®Google Scholar
• Shaw K. M., Stern G. M., Sandler M. Melatonin and parkinsonism. Lancet 1973; 1: 271
   PubMed Web of Science ®Google Scholar
• Shaw K. M., Lees A. J., Stern G. M. The impact of treatment with levodopa in Parkinson's disease. Quarterly Journal of Medicine 1980; 49: 283–293
   PubMedGoogle Scholar
• Stoupel E., Keret R., Assa S., Kaufman H., Shimshoni M., Laron Z. Secretion of growth hormone, prolactin and corticosteroids during different levels of geomagnetic activity. Neuroendocrine Letters 1983; 5: 365–368
   Web of Science ®Google Scholar
• Teychenne P. F., Ziegler M. G., Lake C. R. Low CSF GABA in parkinsonian patients who respond poorly to therapy or suffer from the “on-off” phenomenon. Annals of Neurology 1982; 11: 76–79
   PubMedGoogle Scholar
• Webley G. E., Bohle A., Leidenberger F. A. Positive relationship between the nocturnal concentrations of melatonin and prolactin, and a stimulation of prolactin after melatonin administration in young men. Journal of Pineal Research 1988; 5: 19–33
   PubMedGoogle Scholar
• Weiner W. J., Koller W. C., Perlik S. Drug holiday and the management of Parkinson's disease. Neurology 1980; 30: 1257–1261
   PubMedGoogle Scholar
• Welker H. A., Semm P., Willig R. P., Commentz J. C., Wiltschko W., Vollrath L. Effects of an artificial magnetic field on serotonin N-acetyltransferase activity and melatonin content of the rat pineal gland. Experimental Brain Research 1983; 50: 426–432
   PubMed Web of Science ®Google Scholar
• Wever R. Einfluss Schwacher Elektro-magnetischer Felder auf die Circadiane Periodik des Menschen. Naturwissenschaften 1968; 55: 29–32
   PubMed Web of Science ®Google Scholar
• Zisapel N., Laudon M. Inhibition by melatonin of dopamine release from rat hypothalamus. Brain research 1983; 272: 378–381
   PubMed Web of Science ®Google Scholar
• Zisapel N., Egozi Y., Laudon M. Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Research 1982; 246: 161–163
   PubMed Web of Science ®Google Scholar
• Zisapel N., Egozi Y., Laudon M. Inhibition by melatonin of dopamine release from rat hypothalamus in vitro: variations with sex and the estrous cycle. Neuroendocrinology 1983; 37: 41–47
   PubMed Web of Science ®Google Scholar